1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Secondary Hyperparathyroidism Global Clinical Trials Review, H1, 2014

Secondary Hyperparathyroidism Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Secondary Hyperparathyroidism Global Clinical Trials Review, H1, 2014" provides data on the Secondary Hyperparathyroidism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Secondary Hyperparathyroidism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Secondary Hyperparathyroidism. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Secondary Hyperparathyroidism Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Secondary Hyperparathyroidism 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Secondary Hyperparathyroidism 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Secondary Hyperparathyroidism Therapeutics Clinical Trials 31
Prominent Drugs 33
Clinical Trial Profiles 34
Clinical Trial Overview of Top Companies 34
Amgen Inc. 34
Clinical Trial Overview of Amgen Inc. 34
AbbVie Inc. 37
Clinical Trial Overview of AbbVie Inc. 37
Sanofi 39
Clinical Trial Overview of Sanofi 39
Abbott Laboratories 41
Clinical Trial Overview of Abbott Laboratories 41
Cytochroma Inc. 42
Clinical Trial Overview of Cytochroma Inc. 42
OPKO Health, Inc. 43
Clinical Trial Overview of OPKO Health, Inc. 43
Astellas Pharma Inc. 44
Clinical Trial Overview of Astellas Pharma Inc. 44
Kirin Holdings Company, Limited 45
Clinical Trial Overview of Kirin Holdings Company, Limited 45
Deltanoid Pharmaceuticals Inc. 46
Clinical Trial Overview of Deltanoid Pharmaceuticals Inc. 46
T-cell Technologies, Inc. 47
Clinical Trial Overview of T-cell Technologies, Inc. 47
Clinical Trial Overview of Top Institutes / Government 48
Centre Hospitalier Universitaire Vaudois 48
Clinical Trial Overview of Centre Hospitalier Universitaire Vaudois 48
Atlanta VA Medical Center 49
Clinical Trial Overview of Atlanta VA Medical Center 49
University of California, Los Angeles 50
Clinical Trial Overview of University of California, Los Angeles 50
Creighton University 51
Clinical Trial Overview of Creighton University 51
Roskilde County Hospital 52
Clinical Trial Overview of Roskilde County Hospital 52
Montefiore Medical Center 53
Clinical Trial Overview of Montefiore Medical Center 53
Indiana University School of Medicine 54
Clinical Trial Overview of Indiana University School of Medicine 54
University of Washington 55
Clinical Trial Overview of University of Washington 55
All India Institute of Medical Sciences 56
Clinical Trial Overview of All India Institute of Medical Sciences 56
Weill Cornell Medical College 57
Clinical Trial Overview of Weill Cornell Medical College 57
Five Key Clinical Profiles 58
Appendix 106
Abbreviations 106
Definitions 106
Research Methodology 107
Secondary Research 107
About GlobalData 108
Contact Us 108
Disclaimer 108
Source 108

List of Tables
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Region, 2014* 7
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Secondary Hyperparathyroidism Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Secondary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Secondary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Secondary Hyperparathyroidism Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Secondary Hyperparathyroidism Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Secondary Hyperparathyroidism Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Secondary Hyperparathyroidism Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Secondary Hyperparathyroidism Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Secondary Hyperparathyroidism Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 29
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 34
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 37
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 39
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2014* 41
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytochroma Inc., 2014* 42
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by OPKO Health, Inc., 2014* 43
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014* 44
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Kirin Holdings Company, Limited, 2014* 45
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Deltanoid Pharmaceuticals Inc., 2014* 46
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by T-cell Technologies, Inc., 2014* 47
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Centre Hospitalier Universitaire Vaudois, 2014* 48
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Atlanta VA Medical Center, 2014* 49
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2014* 50
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Creighton University, 2014* 51
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Roskilde County Hospital, 2014* 52
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Montefiore Medical Center, 2014* 53
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Indiana University School of Medicine, 2014* 54
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 55
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2014* 56
Secondary Hyperparathyroidism Therapeutics Clinical Trials Market, Global, Clinical Trials by Weill Cornell Medical College, 2014* 57

List of Figures
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Secondary Hyperparathyroidism Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Secondary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Secondary Hyperparathyroidism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Secondary Hyperparathyroidism to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Secondary Hyperparathyroidism Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Secondary Hyperparathyroidism Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Secondary Hyperparathyroidism Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Secondary Hyperparathyroidism Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 29
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Secondary Hyperparathyroidism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
GlobalData Methodology 107

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global clinical trial imaging market is projected to reach USD 1069.7 million by 2021 from USD 773.4 million in 2016, at a CAGR of 6.7% from 2016 to 2021. Increase in R&D spending and growth in the ...

Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast (2016-2022)

Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast (2016-2022)

  • $ 5274
  • Industry report
  • September 2016
  • by Industry ARC

Pharmacovigilance is referred to as a practice of monitoring the effects of medical drugs after they have been licensed for use, especially in order to identify and evaluate previously unreported adverse ...

Global Clinical Trials Market

December 2016 $ 4250

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.